Fennec Pharmaceuticals Inc. (TSE:FRX - Free Report) - Wedbush increased their Q4 2024 earnings per share estimates for shares of Fennec Pharmaceuticals in a note issued to investors on Sunday, December 22nd. Wedbush analyst D. Nierengarten now anticipates that the biopharmaceutical company will earn $1.88 per share for the quarter, up from their prior estimate of ($0.24). The consensus estimate for Fennec Pharmaceuticals' current full-year earnings is $0.60 per share. Wedbush also issued estimates for Fennec Pharmaceuticals' Q1 2025 earnings at ($0.20) EPS, Q2 2025 earnings at ($0.16) EPS, Q4 2025 earnings at $0.66 EPS and FY2025 earnings at $0.66 EPS.
Separately, Stephens upgraded Fennec Pharmaceuticals to a "strong-buy" rating in a research report on Monday, November 18th.
Check Out Our Latest Stock Report on FRX
Fennec Pharmaceuticals Price Performance
Shares of TSE FRX traded up C$0.02 during trading on Wednesday, reaching C$8.93. The company had a trading volume of 100 shares, compared to its average volume of 2,011. The company has a current ratio of 8.02, a quick ratio of 10.17 and a debt-to-equity ratio of 1,040.68. Fennec Pharmaceuticals has a twelve month low of C$5.65 and a twelve month high of C$15.43. The stock has a 50-day moving average price of C$7.25 and a two-hundred day moving average price of C$7.67. The stock has a market capitalization of C$244.32 million, a PE ratio of 89.30 and a beta of 0.25.
Insider Activity
In other Fennec Pharmaceuticals news, Director Rostislav Christov Raykov purchased 25,000 shares of the stock in a transaction on Friday, December 20th. The stock was bought at an average price of C$3.87 per share, for a total transaction of C$96,840.00. Also, Senior Officer Robert Christopher Andrade acquired 15,816 shares of the company's stock in a transaction dated Monday, November 18th. The shares were bought at an average cost of C$3.43 per share, with a total value of C$54,248.88. Insiders bought a total of 41,612 shares of company stock valued at $157,868 over the last 90 days. Insiders own 16.20% of the company's stock.
About Fennec Pharmaceuticals
(
Get Free Report)
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Featured Articles
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
